Novartis AG
NVSEF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $193,930 | $209,694 | $189,894 | $185,934 |
| - Cash | $11,459 | $13,393 | $7,517 | $12,407 |
| + Debt | $31,258 | $26,348 | $27,964 | $31,093 |
| Enterprise Value | $213,729 | $222,649 | $210,341 | $204,620 |
| Revenue | $51,722 | $46,660 | $51,828 | $52,877 |
| % Growth | 10.8% | -10% | -2% | – |
| Gross Profit | $38,895 | $34,640 | $36,342 | $37,010 |
| % Margin | 75.2% | 74.2% | 70.1% | 70% |
| EBITDA | $20,715 | $19,518 | $15,209 | $17,168 |
| % Margin | 40.1% | 41.8% | 29.3% | 32.5% |
| Net Income | $11,941 | $14,850 | $6,955 | $24,021 |
| % Margin | 23.1% | 31.8% | 13.4% | 45.4% |
| EPS Diluted | 5.87 | 7.58 | 3.27 | 10.65 |
| % Growth | -22.6% | 131.8% | -69.3% | – |
| Operating Cash Flow | $17,619 | $14,458 | $14,236 | $15,071 |
| Capital Expenditures | -$3,814 | -$2,753 | -$2,671 | -$2,971 |
| Free Cash Flow | $13,805 | $11,705 | $11,565 | $12,100 |